Session III:

September 17, 2025
1:00 – 3:30 PM ET

Rebroadcast: 6:30 – 9:00 PM ET

Reducing the Disparity with New Prostate Cancer Treatments and Clinical Trials

This session will review the latest developments in prostate cancer treatments and trends in clinical trials, assessing how these developments may potentially impact the racial disparity in prostate cancer. It will also examine active prostate cancer clinical trials to understand future treatment trends and outline existing opportunities for patients to participate in these trials.

Agenda:

Welcome: Artie Shelton, MD, COL (ret) U.S. Army, PHEN Ambassador

Opening Remarks and Moderator: Keith Crawford, MD, PhD, Director of Clinical Trials and Patient Education, PHEN

Review of New Treatments and Trends: Richard Lee, MD, PhDClinical Co-Director: Claire and John Bertucci Center for Genitourinary Cancers at Mass General Cancer Center, Assistant Professor, Harvard Medical School

Where Are Clinical Trials Leading Us? Alicia K. Morgans, MD, Director of Adult Survivorship, Associate Professor of Medicine, Dana-Farber Cancer Institute, Harvard Medical School 

Reviewing Emerging Clinical Trials: Keith Crawford, MD, PhD, and David Vasir, PhD, Senior Research Analyst, PHEN

Patient Clinical Trial Stories:

Closing Remarks and Survey: Mr. Thomas A. Farrington

SPONSORS

PHEN thanks its sponsors for their support of the 2025 Summit.